Pharmacist-Integrated Multidisciplinary Care in Pregnancy-Associated Breast Cancer

This single-center retrospective series describes real-world chemotherapy regimens, premedication optimization, and maternal-fetal outcomes when clinical pharmacists are embedded in pregnancy-associated breast cancer multidisciplinary teams.

epirubicincyclophosphamidedocetaxelpaclitaxelnab-paclitaxelanthracyclinestaxanesdexamethasoneondansetronpregnancy-associated breast cancerclinical pharmacymultidisciplinary teammaternal-fetal outcomesretrospective cohortoncology pharmacy Oncology Pharmacy

Background Information

Pharmacists enhance pregnancy-related chemotherapy care for breast cancer.

Pregnancy-associated breast cancer (PABC) poses a unique challenge where chemotherapy must balance maternal effectiveness and fetal safety. In this study of 28 patients, 35.71% received anthracycline, cyclophosphamide, and docetaxel. Adverse events included leukopenia and severe myelosuppression (7.14% each). Integration of clinical pharmacists in multidisciplinary teams optimized regimen selection and managed adverse events in PABC care. The study's small sample size limits broader applicability. Clinical pharmacists are vital in managing chemotherapy for PABC, showing promise for improving outcomes.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Liu H, Jin J, Deng Y, Wang X, Zeng T

Citation: Liu H, Jin J, Deng Y, et al. Multidisciplinary management of pregnancy-associated breast cancer: a clinical pharmacy perspective on chemotherapy and perinatal outcomes. Frontiers in oncology. 2026;16:1918932. doi:10.3389/fonc.2026.1918932

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →